聊聊慢性乙肝治疗，先从思路转换说起

jimok001

不严谨，中间太多的直接推论没有依据，都是这样的逻辑推理就没有意义了

清除cccDNA

原帖由 刚必复 于 2009-6-25 09:21 发表



同意，我想换大侠说的就是这个意思，你说得更清楚了。
不知换大侠认为如何？

胡说啦，你们越扯越远了。解决问题不是这样。乱猜想没用，我发表讨论也没用，因为关键两个问题没解决。
换大侠不来看我们这群苍蝇了，人家是什么身份啊，来帮我们，还被恶狗咬。
不知所谓的人很多很多。

某人的媳妇

呵呵 好贴要顶

gtx

好贴要顶，继续顶。。。。。。

zjlh

好贴 由衷地佩服换大侠!!谢谢你的无私奉献

某人的媳妇

LZ失踪了？？？？？？？？？？？？？？？？？

zjlh

好贴 不能沉下去 顶

ZJSXPS

你老婆的乙肝病毒好象是刚染上的、成人绝大多数能自愈、不过乙肝的传染途径是血液、体液[精液]，你老婆是怎么被传染的。

fuck-hbv

楼主
貌似消失好久了

FORRESTFU

Gastroenterol Hepatol. 2009 Jul 2. [Epub ahead of print]

[Efficacy and safety of vaccination against hepatitis A and B in patients with chronic liver disease.][Article in Spanish]

de Artaza Varasa T, Sánchez Ruano JJ, García Vela A, Gómez Rodríguez R, Romero Gutiérrez M, de la Cruz Pérez G, Gómez Moreno AZ, Carrobles Jiménez JM.

Servicio de Aparato Digestivo, Hospital Virgen de la Salud, Toledo, España.

Vaccination to protect against hepatitis A and B should be part of the routine management of patients with chronic liver disease (CLD). OBJECTIVES: To evaluate the efficacy and safety of hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccination in a group of patients with CLD and to assess the presence of factors predictive of response. PATIENTS AND METHODS: We performed a prospective, single-center study in 194 patients (123 men, 71 women; mean age, 48.9+/-10.7 years) with CLD: 107 with chronic hepatitis (CH) and 87 with hepatic cirrhosis (HC), all Child-Pugh class A. The most frequent causes of CLD were HCV infection and alcohol. Patients negative for anti-HAV IgG received the HAV vaccination (1440 ELISA units in two doses) and those with negative HBV serology received the HBV vaccination ( three 20mug doses). Patients with inadequate response to the latter vaccine received an additional double dose. Thirty patients received a combination vaccine (three doses). RESULTS: Sixty patients (31%) received the HAV vaccine and 150 (77%) patients received the HBV vaccine. Seroconversion was achieved by 91.6% of patients for HAV and by 57% of the patients for HBV. After the additional dose, the response increased to 74%. Efficacy was similar between CH and HC. HBV vaccination was less effective in HC than in CH and the seroconversion rate was significantly lower in patients with HC and previous decompensation. The combination vaccine (30 patients) was highly im munogenic. No adverse effects were registered. CONCLUSIONS: HAV vaccination has high efficacy in patients with CLD. Patients with HC respond weakly to HBV vaccination compared with those with CH and especially if there is prior decompensation. The combination vaccine seems particularly effective in patients with CLD. The three vaccines are safe.

PMID: 19577338 [PubMed - as supplied by publisher]